title: Investigating the potential of conserved inner core oligosaccharide regions of Moraxella catarrhalis lipopolysaccharide as vaccine antigens: accessibility and functional activity of monoclonal antibodies and glycoconjugate derived sera.
abstract: We investigated the conservation and antibody accessibility of inner core epitopes of Moraxella catarrhalis lipopolysaccharide (LPS) in order to assess their potential as vaccine candidates. Two LPS mutants, a single mutant designated lgt2 and a double mutant termed lgt2/lgt4, elaborating truncated inner core structures were generated in order to preclude expression of host-like outer core structures and to create an inner core structure that was shared by all three serotypes A, B and C of M. catarrhalis. Murine monoclonal antibodies (mAbs), designated MC2-1 and MC2-10 were obtained by immunising mice with the lgt2 mutant of M. catarrhalis serotype A strain. We showed that mAb MC2-1 can bind to the core LPS of wild-type (wt) serotype A, B and C organisms and concluded that mAb MC2-1 defines an immunogenic inner core epitope of M. catarrhalis LPS. We were unsuccessful in obtaining mAbs to the lgt2/lgt4 mutant. MAb MC2-10 only recognised the lgt2 mutant and the wt serotype A strain, and exhibited a strong requirement for the terminal N-acetyl-glucosamine residue of the lgt2 mutant core oligosaccharide, suggesting that this residue was immunodominant. Subsequently, we showed that both mAbs MC2-1 and MC2-10 could facilitate bactericidal killing of the lgt2 mutant, however neither mAb could facilitate bactericidal killing of the wt serotype A strain. We then confirmed and extended the candidacy of the inner core LPS by demonstrating that it is possible to elicit functional antibodies against M. catarrhalis wt strains following immunisation of rabbits with glycoconjugates elaborating the conserved inner core LPS antigen. The present study describes three conjugation strategies that either uses amidases produced by Dictyostelium discoideum, targeting the amino functionality created by the amidase activity as the attachment point on the LPS molecule, or a strong base treatment to remove all fatty acids from the LPS, thus creating amino functionalities in the lipid A region to conjugate via maleimide-thiol linker strategies targeting the carboxyl residues of the carrier protein and the free amino functionalities of the derived lipid A region of the carbohydrate resulted in a high loading of carbohydrates per carrier protein from these carbohydrate preparations. Immunisation derived antisera from rabbits recognised fully extended M. catarrhalis LPS and whole cells. Moreover, bactericidal activity was demonstrated to both the immunising carbohydrate antigen and importantly to wt cells, thus further supporting the consideration of inner core LPS as a potential vaccine antigen to combat disease caused by M. catarrhalis.
authors: Institute for Biological Sciences, National Research Council, Ottawa, ON, K1A 0R6, Canada. Andrew.Cox@nrc-cnrc.gc.ca
authors: Andrew D
authors: AD
authors: Cox
authors: Frank
authors: F
authors: St Michael
authors: Chantelle M
authors: CM
authors: Cairns
authors: Suzanne
authors: S
authors: Lacelle
authors: Amy Lea
authors: AL
authors: Filion
authors: Dhamodharan
authors: D
authors: Neelamegan
authors: Cory Q
authors: CQ
authors: Wenzel
authors: Heather
authors: H
authors: Horan
authors: James C
authors: JC
authors: Richards
references: Infect Immun. 2001 Mar;69(3):1358-63
references: 11179299
references: J Clin Microbiol. 1977 Feb;5(2):227-35
references: 845247
references: Infect Immun. 2007 Jun;75(6):2974-80
references: 17371852
references: Vaccine. 2005 Oct 17;23(43):5045-54
references: 16046037
references: Infect Immun. 1999 Oct;67(10):5417-26
references: 10496924
references: Infect Immun. 2003 Apr;71(4):1843-8
references: 12654799
references: Science. 2004 Jul 23;305(5683):522-5
references: 15273395
references: J Clin Microbiol. 1990 Dec;28(12):2627-31
references: 1704012
references: Expert Rev Vaccines. 2009 Jan;8(1):77-90
references: 19093775
references: Microb Pathog. 1998 May;24(5):299-308
references: 9600862
references: Carbohydr Res. 2002 Sep 9;337(16):1435-44
references: 12204604
references: Infect Immun. 2000 Sep;68(9):4980-5
references: 10948114
references: Expert Rev Vaccines. 2005 Dec;4(6):843-53
references: 16372880
references: Carbohydr Res. 1996 Dec 13;295:127-46
references: 9002189
references: Infect Immun. 2008 Sep;76(9):4251-8
references: 18559429
references: FEBS J. 2007 Apr;274(8):2024-37
references: 17388814
references: Infect Immun. 1998 May;66(5):1891-7
references: 9573066
references: Nature. 1970 Aug 15;227(5259):680-5
references: 5432063
references: Clin Diagn Lab Immunol. 1996 May;3(3):351-4
references: 8705682
references: Microbes Infect. 2000 Apr;2(5):547-59
references: 10865200
references: J Immunol Methods. 1989 Jun 2;120(1):133-43
references: 2499636
references: Am J Respir Crit Care Med. 2005 Jul 15;172(2):195-9
references: 15805178
references: Vaccine. 2011 Jun 6;29(25):4210-7
references: 21501641
references: EMBO J. 1982;1(8):1017-22
references: 16453425
references: Infect Immun. 2009 Oct;77(10):4548-58
references: 19651870
references: Infect Immun. 2002 Nov;70(11):5982-9
references: 12379673
references: FEMS Immunol Med Microbiol. 2004 Jun 1;41(2):109-15
references: 15145454
references: Glycoconj J. 2010 May;27(4):401-17
references: 20340043
references: Clin Vaccine Immunol. 2006 Sep;13(9):1052-6
references: 16960118
references: Vaccine. 1995 Apr;13(5):463-70
references: 7543714
references: Am J Manag Care. 2005 Aug;11(6 Suppl):S202-10
references: 16111443
references: Carbohydr Res. 1995 Jan 17;266(2):237-61
references: 7535189
references: Vet Microbiol. 2006 Aug 25;116(1-3):175-86
references: 16750602
references: Infect Immun. 2005 May;73(5):2790-6
references: 15845482